Metabolic Effects of Hydroxychloroquine (MetaHcQ)
Sponsor: Washington University School of Medicine
Terminated
COVID-19 \& loss of funding
Other terminated trials from Washington University School of Medicine
- Gynecologic Cancer · Phase NA · Oct 2025
- Extensive-stage Small Cell Lung Cancer · Phase PHASE2 · Aug 2025
- Schizophrenia · Phase PHASE1 · Jan 2025
- Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery · Phase PHASE4 · Dec 2024
- Recurrent Rectal Cancer · Phase NA · Nov 2024
See all terminations from Washington University School of Medicine
Other Type 2 Diabetes Mellitus trials with similar outcome
Listed as NCT02026232, this NA trial focuses on Type 2 Diabetes Mellitus and remains terminated or withdrawn. Sponsored by Washington University School of Medicine, it has been updated 12 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2024 — Jul 2024 [monthly]
Terminated NA
Status: Suspended → Terminated
-
Jul 2022 — Jan 2024 [monthly]
Suspended NA
▶ Show 7 earlier versions
-
Sep 2021 — Jul 2022 [monthly]
Suspended NA
-
Jan 2021 — Sep 2021 [monthly]
Suspended NA
-
Jun 2020 — Jan 2021 [monthly]
Suspended NA
Status: Recruiting → Suspended
-
May 2019 — Jun 2020 [monthly]
Recruiting NA
-
Jun 2018 — May 2019 [monthly]
Recruiting NA
-
Apr 2018 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .